J. Wrammert

XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants

The paper evaluates the effectiveness of an XBB.1.5 monovalent booster vaccine, showing improved antibody binding and neutralization against SARS-CoV-2 Omicron variants.

Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response

The paper identifies three monoclonal antibodies that poorly neutralize the Omicron BA.1 variant, revealing structural and molecular features of antibody evasion.

Epistasis reduces fitness costs of influenza A virus escape from stem-binding antibodies

This study shows that influenza A virus escape from stem-binding antibodies incurs fitness costs, but epistatic interactions can mitigate these costs in some contexts.

Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody

This paper identifies and structurally analyzes an antibody that neutralizes SARS-CoV-2 BA.1 and BA.2 variants, revealing its unique epitope and mechanism of action.

Development of a monoclonal antibody to a vibriophage as a proxy for Vibrio cholerae detection

This study develops a monoclonal antibody to the vibriophage ICP1 to improve cholera detection in rapid diagnostic tests by detecting the phage as a proxy for Vibrio cholerae.

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant

This study evaluates the neutralizing activity of mRNA vaccines against the SARS-CoV-2 Omicron variant, showing reduced efficacy after the second dose but improved responses following a third dose.

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant

This study assesses neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant in convalescent and vaccinated individuals, finding it is 6.8-fold more resistant but still neutralizable.

Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant

The paper compares antibody binding and neutralization against SARS-CoV-2 B.1 and B.1.351 variants in infected and vaccinated individuals, finding reduced titers but retained neutralization.

Humans surviving cholera develop antibodies against Vibrio cholerae O-specific polysaccharide that inhibit pathogen motility

This study shows that antibodies against Vibrio cholerae O-specific polysaccharide inhibit bacterial motility and provide protection against cholera in a murine model.

Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India

This study examines humoral and memory B cell responses in Indian COVID-19 recovered individuals, finding that RBD-specific IgG correlates with neutralizing antibodies and can serve as a surrogate for neutralization assays.